BioCentury | Jul 17, 2019
Financial News

Korea’s Orum stays local with $30M round to build out cell-penetrating platform

...its cell-penetrating antibody platform and build out its R&D labs in Boston and South Korea, Orum...
...KB Investment/Solidus Investment also participated. As with its $8 million series A round in 2017, Orum Therapeutics Inc....
...such as Ras that are hard to target with small molecules (see "Orum's Forum" ). Orum's...
BioCentury | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

...has clearly shown that exosomes are better than liposomes at targeting Ras.” Sung Joo Lee, Orum...
...approaches to target Ras. Orum Therapeutics Inc. is developing cell-permeable antibodies against KRAS and other intracellular targets. Orum...
...as complementary rather than in direct competition. He said the difference between them is that Orum’s...
BioCentury | Jun 16, 2017
Finance

Starting local, going global

...antibody company sees pharma partners and international VCs as its ticket to the global market. Orum...
...A round on June 14 from Korean investors InterVest, KB Investment/Solidus Investment and LB Investment. Orum's...
...Korea." Sung Joo Lee, Orum In a paper published last month in Nature Communications , Orum...
BioCentury | Jun 16, 2017
Financial News

Orum raises $8M in series A

...Antibody company Orum Therapeutics Inc. (Daejeon, South Korea) raised $8 million in a series A round on June...
...14. Investors included InterVest, KB Investment/Solidus Investment and LB Investment. Orum Therapeutics Inc. , Daejeon, South Korea Chris Lieu Orum Therapeutics Inc....
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

...partnering with Complix N.V. to use the biotech’s Alphabody platform for reaching intracellular targets, and Orum Therapeutics Inc....
...launched to use a cell-penetrating antibody technology from Ajou University for creating cancer therapeutics. Yesterday, Orum...
...two companies have developed technologies to transport larger antibodies (dark blue) across the cell membrane. Orum Therapeutics Inc....
BioCentury | Jun 14, 2017
Financial News

Orum raises $8M in series A

...Antibody company Orum Therapeutics Inc. (Daejeon, South Korea) raised $8 million in a series A round. Investors included...
...Investors included InterVest, KB Investment/Solidus Investment and LB Investment. InterVest's Yeo Jung Moon will join Orum's...
...Jan. 4) . In a paper published last month in Nature Communications , researchers from Orum...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cancer

...increased survival compared with Erbitux alone or Erbitux plus the control antibody. Ongoing work by Orum Therapeutics Inc....
...KRAS, in preclinical testing for cancer. TARGET/MARKER/PATHWAY: K-Ras (KRAS) LICENSING STATUS: Patent applications filed by Orum Therapeutics Inc....
...May 10, 2017 doi:10.1038/ncomms15090 CONTACT: Yong-Sung Kim, Ajou University, Suwon, South Korea email: kimys@ajou.ac.kr Lauren Martz Ajou University Orum Therapeutics Inc. K-Ras...
BioCentury | May 15, 2017
Clinical News

Orum team describes cell-permeable, Ras-targeting mAb

...group included scientists from Orum Therapeutics Inc. (Daejeon, South Korea), who used the company's cell-penetrating technology platform. Orum’s...
...the technology, to which Orum holds a license. Kim is a scientific co-founder at Orum. Becky Simon Orum Therapeutics Inc. K-Ras...
BioCentury | Jan 4, 2017
Emerging Company Profile

Orum’s forum

...membranes on their own, and those entering cells via endocytosis degrade before reaching the cytosol. Orum Therapeutics Inc....
...but get them out of endosomes before they are flagged for lysosomal degradation. Lee is Orum’s...
...cells and bound its target, demonstrating the engineered V L did not impede antibody binding. Orum...
BioCentury | Dec 15, 2016
Product R&D

p53 and Ras: Back from the dead

...p53 mutants Preclinical Ras Antibody LA Cell Inc. Cell-penetrating antibody targeting mutant KRAS Discovery Antibody Orum Therapeutics Inc....
...proteins, with new technologies that allow the proteins to reach the previously inaccessible intracellular target. Orum Therapeutics Inc....
...Inc. are developing platforms for cell-penetrating antibodies, both opting for KRAS as an initial target. Orum...
Items per page:
1 - 10 of 13
BioCentury | Jul 17, 2019
Financial News

Korea’s Orum stays local with $30M round to build out cell-penetrating platform

...its cell-penetrating antibody platform and build out its R&D labs in Boston and South Korea, Orum...
...KB Investment/Solidus Investment also participated. As with its $8 million series A round in 2017, Orum Therapeutics Inc....
...such as Ras that are hard to target with small molecules (see "Orum's Forum" ). Orum's...
BioCentury | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

...has clearly shown that exosomes are better than liposomes at targeting Ras.” Sung Joo Lee, Orum...
...approaches to target Ras. Orum Therapeutics Inc. is developing cell-permeable antibodies against KRAS and other intracellular targets. Orum...
...as complementary rather than in direct competition. He said the difference between them is that Orum’s...
BioCentury | Jun 16, 2017
Finance

Starting local, going global

...antibody company sees pharma partners and international VCs as its ticket to the global market. Orum...
...A round on June 14 from Korean investors InterVest, KB Investment/Solidus Investment and LB Investment. Orum's...
...Korea." Sung Joo Lee, Orum In a paper published last month in Nature Communications , Orum...
BioCentury | Jun 16, 2017
Financial News

Orum raises $8M in series A

...Antibody company Orum Therapeutics Inc. (Daejeon, South Korea) raised $8 million in a series A round on June...
...14. Investors included InterVest, KB Investment/Solidus Investment and LB Investment. Orum Therapeutics Inc. , Daejeon, South Korea Chris Lieu Orum Therapeutics Inc....
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

...partnering with Complix N.V. to use the biotech’s Alphabody platform for reaching intracellular targets, and Orum Therapeutics Inc....
...launched to use a cell-penetrating antibody technology from Ajou University for creating cancer therapeutics. Yesterday, Orum...
...two companies have developed technologies to transport larger antibodies (dark blue) across the cell membrane. Orum Therapeutics Inc....
BioCentury | Jun 14, 2017
Financial News

Orum raises $8M in series A

...Antibody company Orum Therapeutics Inc. (Daejeon, South Korea) raised $8 million in a series A round. Investors included...
...Investors included InterVest, KB Investment/Solidus Investment and LB Investment. InterVest's Yeo Jung Moon will join Orum's...
...Jan. 4) . In a paper published last month in Nature Communications , researchers from Orum...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cancer

...increased survival compared with Erbitux alone or Erbitux plus the control antibody. Ongoing work by Orum Therapeutics Inc....
...KRAS, in preclinical testing for cancer. TARGET/MARKER/PATHWAY: K-Ras (KRAS) LICENSING STATUS: Patent applications filed by Orum Therapeutics Inc....
...May 10, 2017 doi:10.1038/ncomms15090 CONTACT: Yong-Sung Kim, Ajou University, Suwon, South Korea email: kimys@ajou.ac.kr Lauren Martz Ajou University Orum Therapeutics Inc. K-Ras...
BioCentury | May 15, 2017
Clinical News

Orum team describes cell-permeable, Ras-targeting mAb

...group included scientists from Orum Therapeutics Inc. (Daejeon, South Korea), who used the company's cell-penetrating technology platform. Orum’s...
...the technology, to which Orum holds a license. Kim is a scientific co-founder at Orum. Becky Simon Orum Therapeutics Inc. K-Ras...
BioCentury | Jan 4, 2017
Emerging Company Profile

Orum’s forum

...membranes on their own, and those entering cells via endocytosis degrade before reaching the cytosol. Orum Therapeutics Inc....
...but get them out of endosomes before they are flagged for lysosomal degradation. Lee is Orum’s...
...cells and bound its target, demonstrating the engineered V L did not impede antibody binding. Orum...
BioCentury | Dec 15, 2016
Product R&D

p53 and Ras: Back from the dead

...p53 mutants Preclinical Ras Antibody LA Cell Inc. Cell-penetrating antibody targeting mutant KRAS Discovery Antibody Orum Therapeutics Inc....
...proteins, with new technologies that allow the proteins to reach the previously inaccessible intracellular target. Orum Therapeutics Inc....
...Inc. are developing platforms for cell-penetrating antibodies, both opting for KRAS as an initial target. Orum...
Items per page:
1 - 10 of 13